Rep. Julie Johnson Sells Medtronic PLC (NYSE:MDT) Shares

Key Points

• Representative Julie Johnson sold shares of Medtronic PLC (NYSE:MDT) for an amount between $1,001 and $15,000 on August 14th, as disclosed in a filing on September 11th.
• Despite a slight decline in stock price, Medtronic reported a 7.7% increase in quarterly revenue year-over-year, with an earnings per share (EPS) of $1.26 exceeding estimates.
• The company declared a quarterly dividend of $0.71, with a 3.0% yield and a payout ratio of 78.24%, set to be paid on October 17th.

Representative Julie Johnson (D-Texas) recently sold shares of Medtronic PLC NYSE: MDT. In a filing disclosed on September 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Medtronic stock on August 14th. The trade occurred in the Representative's "CHASE BROKERAGE ACCOUNT (3935)" account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of McDonald's NYSE: MCD on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Parker-Hannifin NYSE: PH on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Charles Schwab NYSE: SCHW on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Fidelity National Information Services NYSE: FIS on 8/14/2025.
• Sold $1,001 - $15,000 in shares of ConocoPhillips NYSE: COP on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Home Depot NYSE: HD on 8/14/2025.
• Sold $1,001 - $15,000 in shares of Dover NYSE: DOV on 8/14/2025.
• Sold $1,001 - $15,000 in shares of UnitedHealth Group NYSE: UNH on 8/14/2025.

Medtronic Trading Down 0.2%

Medtronic stock traded down $0.20 during mid-day trading on Friday, hitting $94.05. The stock had a trading volume of 7,334,188 shares, compared to its average volume of 6,888,095. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54. Medtronic PLC has a 12 month low of $79.29 and a 12 month high of $96.25. The stock has a market capitalization of $120.64 billion, a PE ratio of 25.91, a P/E/G ratio of 2.48 and a beta of 0.77. The stock has a 50-day simple moving average of $91.50 and a two-hundred day simple moving average of $88.27.

Medtronic (NYSE:MDT - Get Free Report) last announced its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.23 by $0.03. The business had revenue of $8.58 billion for the quarter, compared to analyst estimates of $8.37 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.Medtronic's revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. As a group, sell-side analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 17th. Investors of record on Friday, September 26th will be issued a $0.71 dividend. The ex-dividend date is Friday, September 26th. This represents a $2.84 annualized dividend and a yield of 3.0%. Medtronic's dividend payout ratio (DPR) is currently 78.24%.

Wall Street Analyst Weigh In

MDT has been the subject of several analyst reports. Sanford C. Bernstein increased their price objective on Medtronic from $97.00 to $98.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 20th. Mizuho lifted their price objective on Medtronic from $98.00 to $100.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. Leerink Partnrs upgraded Medtronic to a "strong-buy" rating in a research report on Monday, June 16th. Wolfe Research upgraded Medtronic from an "underperform" rating to a "peer perform" rating in a research report on Monday, June 30th. Finally, Leerink Partners started coverage on Medtronic in a report on Monday, June 16th. They issued an "outperform" rating and a $110.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, Medtronic currently has a consensus rating of "Moderate Buy" and a consensus target price of $102.14.

Insider Activity

In other Medtronic news, Director William R. Jellison bought 2,500 shares of the business's stock in a transaction on Monday, August 25th. The stock was bought at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the transaction, the director owned 5,000 shares in the company, valued at approximately $461,850. The trade was a 100.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Harry Skip Kiil sold 8,605 shares of the business's stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the sale, the executive vice president owned 35,615 shares of the company's stock, valued at approximately $3,261,621.70. This represents a 19.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.26% of the stock is owned by company insiders.

Institutional Trading of Medtronic

A number of hedge funds have recently made changes to their positions in the stock. 1248 Management LLC purchased a new position in Medtronic in the first quarter worth about $26,000. Burkett Financial Services LLC grew its stake in Medtronic by 185.0% during the 1st quarter. Burkett Financial Services LLC now owns 285 shares of the medical technology company's stock valued at $26,000 after acquiring an additional 185 shares in the last quarter. Delos Wealth Advisors LLC purchased a new stake in shares of Medtronic in the 2nd quarter valued at approximately $27,000. Columbia River Financial Group LLC purchased a new position in shares of Medtronic during the 1st quarter worth approximately $28,000. Finally, Twin Tree Management LP acquired a new stake in Medtronic during the 1st quarter worth $29,000. 82.06% of the stock is owned by institutional investors.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas' 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. Johnson (Democratic Party) ran for election to the U.S. House to represent Texas' 32nd Congressional District. She won in the general election on November 5, 2024. Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson's career experience includes working as an attorney.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.